AtriCure publishes Q3 2026 earnings call transcript
ATRC•AtriCure reported third-quarter revenue of $154.5 million, up 15%, and raised its full-year adjusted EBITDA guidance to $91 million-$94 million. It expects full-year revenue of $606 million-$610 million.
1. Quarterly results
AtriCure's November 4 third-quarter 2026 earnings call featured CEO Michael Carrel, CFO Angie Wirick and equity analysts. Revenue rose 15% to $154.5 million, driven by pain management, open ablation and appendage management.
2. Full-year outlook
Management raised full-year adjusted EBITDA guidance to $91 million-$94 million and expects revenue of $606 million-$610 million. The outlook remains cautious amid U.S. hybrid ablation weakness and international headwinds, with no significant overseas recovery expected this year.
3. BoxX-NoAF trial
BoxX-NoAF enrollment remains on track for completion by year-end, with initial data expected in spring 2027. FDA approval is anticipated around mid-2028.
